Transmedics Group (TMDX) Stock Price
Transmedics Group Price
Revenue has compounded at 66.3% per year over the past 9 years to 605.49 M USD. Transmedics Group's net margin stands at 31.4%, up from -146.1% several years earlier. Analysts set a median price target of 95.00 USD, implying 11.4% above the current price. Of 19 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 37% above its 52-week low.
Transmedics Group stock price
Transmedics Group business model & stock analysis
Frequently asked questions about Transmedics Group
Transmedics Group Inc. operates under a business model focused on the development and commercialization of organ transplant solutions. The company specializes in designing and producing innovative medical devices and systems that preserve, monitor, and assess organs intended for transplantation. By harnessing cutting-edge technology, Transmedics' business model aims to improve both donor organ quality and transplantation outcomes. Through its offerings, the company seeks to address critical challenges faced by organ transplant patients and healthcare professionals worldwide. Transmedics Group Inc. continues to drive innovation in the organ transplant field through its comprehensive product portfolio and commitment to advancing patient care.
Transmedics Group Inc is primarily active in the biomedical industry.
The main competitors of Transmedics Group Inc in the market include Medtronic, Inc., XVIVO Perfusion AB, and OrganAssist BV.
Transmedics Group Inc is a leading medical technology company specializing in organ transplant solutions. Founded in 1998, the company has been dedicated to improving outcomes for patients awaiting organ transplants. With its groundbreaking Organ Care System (OCS), Transmedics revolutionized the field by allowing organs to be preserved and assessed outside the traditional cold storage method. This breakthrough technology ensures organs remain at the optimal physiological condition, significantly increasing the chances of successful transplants. Transmedics is committed to continuing innovation and expanding its global presence to address the critical need for organ transplantation worldwide.
Transmedics Group Inc has achieved several significant milestones. Notably, the company successfully developed the Organ Care System (OCS), a breakthrough technology that allows for the preservation and transportation of donor organs. The OCS has revolutionized the field of transplant medicine by extending the time organs can remain outside the body, increasing the chances of successful transplantation. Additionally, Transmedics Group Inc received regulatory approvals for the OCS in major markets, including the United States and Europe. These achievements have solidified the company's position as a leader in the advancement of organ transplantation, benefiting countless patients worldwide.
Transmedics Group Inc is primarily present in the United States.
Transmedics Group Inc represents a commitment to innovation and improving organ transplant outcomes. The company's corporate philosophy centers around its Organ Care System (OCS) technology, which enables the preservation and assessment of donated organs for transplantation. Transmedics Group Inc values the advancements made in organ transplantation, aiming to improve patient outcomes and increase the number of viable organs available for transplant. By leveraging their OCS technology, the company strives to address the critical organ shortage challenge and revolutionize the transplantation field. Through their dedication to innovation and patient-centric approach, Transmedics Group Inc constantly aims to make a positive impact in the field of organ transplantation.
Analysts currently set an average price target of 96.86 USD for the Transmedics Group stock (median: 95.00 USD), implying +13.6 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the Transmedics Group stock: 13 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Transmedics Group to generate revenue of 743.10 M USD and earnings per share of 1.24 USD.
Converted at the current exchange rate, the Transmedics Group share trades at 74.84 EUR (85.29 USD).
The Transmedics Group share (TMDX) is listed on 3 stock exchanges, including: NASDAQ (TMDX), Frankfurt (8T8.F), München (8T8.MU).
The Transmedics Group Inc is a leading provider of advanced organ care systems for transplantation medicine. The company offers an innovative platform that allows organs to be obtained, protected, transported, and transplanted outside of the body. The company is divided into three main business areas: 1. Organ Care System The Organ Care System (OCS) is a groundbreaking technology that revolutionizes organ care and transplantation. It is a portable, modular system that enables doctors to obtain and protect donor organs outside of the body. The OCS was developed to increase the survival rate of donor organs and reduce the number of transplant rejections. 2. Organ Transport & Storage Solutions The company offers a variety of organ transport and storage solutions that meet the needs of customers. The transport and storage systems are FDA-certified and provide optimal conditions for successful transplantation. 3. Organ Care Services Organ Care Services (OCS) are a key part of Transmedics' business operations. The company offers a wide range of services tailored to the specific needs of customers. These include organ storage, preparation for transplantation, and support during surgeries. Transmedics is an innovative company protected by a number of patents and intellectual property. The company heavily invests in research and development and stays at the forefront of technology to maintain its position as a leader in organ transplantation. In summary, Transmedics Group Inc is a pioneer in the field of organ transplantation. With its offering of advanced organ care systems, the company has revolutionized transplantation medicine and established itself as a leading provider. Transmedics is well-positioned to continue growing and meeting the needs of its customers while helping to save lives.
The expected revenue of Transmedics Group is 743.10 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Transmedics Group is 50.69 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Transmedics Group is currently 68.87. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Transmedics Group stock.
The price-to-sales ratio (P/S) of Transmedics Group is currently 4.70. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Transmedics Group stock.
The Eulerpool Quality Score for Transmedics Group is 6/10.
The ISIN of Transmedics Group is US89377M1099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Transmedics Group is A2PH5P. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Transmedics Group is TMDX. The ticker symbol is used to trade Transmedics Group shares on the stock exchange.
Transmedics Group paid dividends every year for the past 0 years.
Transmedics Group is assigned to the 'Health' sector.
The dividends of Transmedics Group are distributed in USD.
Transmedics Group stock
Transmedics Group Peer Group
Transmedics Group Ticker
Transmedics Group FIGI
All fundamentals and in-depth analysis of Transmedics Group
Our stock analysis for Transmedics Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Transmedics Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.